SPAC Good Works II indicators letter of intent to mix with Direct Biologics (NASDAQ:GWII)

SPAC Good Works II Acquisition Corp. (NASDAQ:GWII) has signed a letter of intent to merge with regenerative drugs therapy developer Direct Biologics in a deal that pegs the enterprise worth of the corporate at $675M.

Underneath the settlement, the corporations will negotiate completely till Nov. 21. The proposed transaction requires the mixed firm to have a minimum of $75M in internet money at time of closing.

The transaction is anticipated to generate gross proceeds of $331M, assuming no redemptions and together with proceeds from a $100M public placement. The deal is anticipated to shut through the first half of 2023, topic to sure circumstances.

Good Works stated that it intends to carry a shareholders vote on Oct. 11 over extending the corporate’s deadline to consummate a enterprise mixture to April 14 from Oct. 14. Shareholders will even have a chance to redeem shares on the assembly.

Direct Biologics’ lead product, ExoFlo, is in Part 3 testing for the therapy of moderate-to-severe acute respiratory misery syndrome, or ARDS, in hospitalized sufferers with severe-to-critical COVID-19.

The corporate is planning to begin scientific testing of the product in late 2022 and early 2023 for indications similar to ulcerative colitis, Crohn’s illness and stomach strong organ transplantation.

For extra SPAC information, try SA’s SPAC Information web page.